MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_01C7EB01.76A7EDC0" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer. ------=_NextPart_01C7EB01.76A7EDC0 Content-Location: file:///C:/9282BE47/drugpatchblog.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii" Dangers of drug patches overlooked

 

Dangers of drug patches overlooked

 =

The FDA has cautioned about delivering painkiller fentanyl through the skin, but healthcare providers d= on't seem to be getting the message. Other drugs pose problems too.

By Ricardo Alonso-Zaldivar, Los Angeles Times Staff Writer
August 27, 2007

WASHINGTON -- Army Master Sgt. Harold Kinamon entered a milit= ary hospital in Ohio for routine respiratory surgery to help him sleep better. = The operation, in October 2005, progressed smoothly. He went home with nothing = more than a raw throat and a painkiller contained in an adhesive patch on his sk= in.

That night, Kinamon, 41, di= ed in his sleep -- killed by an overdose of the drug delivered through the patch.=

What made his death even more tragic was that the dangers of using skin pat= ches to administer the particular painkiller he received, an opiumlike drug called fentanyl, were clearly understood a= t the time. Only three months earlier, the Food and Drug Administration -- respon= ding to a number of similar deaths -- had issued a strong warning: Though benefi= cial under appropriate conditions, fentanyl patches = should be used with great caution, and not for postoperative pain relief.

Kinamon's death reflects more than an individual misfortune. Healthcare providers nationwide are still not getting the messa= ge as fentanyl patches continue to be implicated in scores of deaths.

Failure to solve the problem is all the more serious because the use of pat= ches is spreading to other drugs, including other painkillers, contraceptives and medications for children with attention deficit disorder. Moreover, a new generation of high-tech patches is expected to make many more drugs availab= le in patch form.

The benefits of patches have been accompanied by problems, replicating a pattern common to many medical advances: Breakthroughs often come with risks and downsides that may not be fully recognized until later.

Drug safety experts are urging the FDA to reexamine the issue of medicinal patches. One primary problem seems to be how to get the right dose of a drug through a patch for different patients under differing conditions.

Patches are "a neat way of delivering drugs," but they are not an unalloyed blessing, said Dr. Curt D. Furberg of= the Wake Forest University medical school.

The appeal of the patches is clear: They solve a host of problems with more traditional methods of administering medications. Unlike injections, they d= on't hurt. Unlike pills, they don't have to be swallowed. They resolve the common problem of patients not taking drugs in the right amount at the prescribed intervals. And their medicine enters the bloodstream directly, rather than = via the stomach.

Those advantages are real, medical experts say, but they are not the whole story.

Sales of Ortho Evra, the first birth-control pa= tch, plunged last year after the FDA cautioned that it exposed women to higher levels of a hormone linked to dangerous blood clots than do oral contraceptives.

With pills, the drug level spikes after consumption, dropping as the time f= or the next dose approaches. Patches maintain a steadier level, but, over time, this can lead to higher total exposure to the drug. That can cause problems, and the trade-offs are not well understood, experts say.

"What is the corresponding patch level that would be equivalent to oral drugs?" Furberg asked. "People use different formulas and there is disagreement."

The Daytrana patch for attention deficit disord= er recently ran into problems. Opening the patch and getting it to stick was d= ifficult. (The maker says the adhesion problem has been fixed.) And the medication can irritate the skin, causing welts. The FDA is investigating.

The effect of any patch can vary considerably from patient to patient. "Some people may not get enough of the drug, which defeats the purpose= of taking it. And some may get too much . . . which is going to hurt some people," Furberg said.

For instance, heat affects the rate at which the skin absorbs a drug. Sunbathing, a hot shower or exercise can trigger an overdose.

Also, some people have thicker skin, which is more resistant to absorbing a drug. Speed of absorption can vary by a factor of about three, which can complicate finding the right dosage.

Another problem is psychological: Patients and medical professionals have a tendency to see patches as benign devices akin to a bandage. It's easy to forget the powerful, potentially dangerous drug within.

"Patches are not innocuous," said Kenneth Sloan, a medicinal chem= ist at the University of Florida whose research has shown wide variations in how quickly individuals absorb drugs through the skin. "One patch does not= fit all."

That's why the FDA said in July 2005 that in the case of fentanyl, patches should be prescribed at the lowest practicable dose, should not be = used to treat short-term pain or pain after an operation, and should only be use= d by patients already established on opioid drugs. <= o:p>

 

IF YOU SUSPECT THAT YOU OR A LOVED ONE HAS BEEN INJUR= ED AS A RESULT OF A DRUG PATCH, CONTACT AVERY LAW FIRM FOR A FREE CONSULTATION.  IF YOUR CASE IS ACCEPTED, AVERY LA= W FIRM WILL HANDLE THE CASE ON A CONTINGENCY FEE BASIS, MEANING THERE IS NO ATTORNEY’S FEE UNLESS THERE IS A RECOVERY, AND THEN YOU PAY A PERCENT= AGE OF THE RECOVERY.

 

AVERY LAW FIRM

New York-Colorado-Indiana

&nb= sp;A Nationally Prominent Personal Injury Law Firm. <= span style=3D'font-family:Arial;mso-bidi-font-family:"Times New Roman"'>

= “Honest, Experienced, Well Respected.”

ALL CASES HANDLED ON CONTINGENCY FEE BASIS

NO RECOVERY, NO ATTORNEYS FEES

FREE CONSULTATIONS!

CALL NOW! 1-866-9-URGENT Toll free (nationwide)

or (866) 987-4368

Email AVERY LAW FIRM (click here)

 

Return to HOME= PAGE (click here)

 

------=_NextPart_01C7EB01.76A7EDC0 Content-Location: file:///C:/9282BE47/drugpatchblog_files/image004.jpg Content-Transfer-Encoding: base64 Content-Type: image/jpeg /9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAoHBwgHBgoICAgLCgoLDhgQDg0NDh0VFhEYIx8lJCIf IiEmKzcvJik0KSEiMEExNDk7Pj4+JS5ESUM8SDc9Pjv/2wBDAQoLCw4NDhwQEBw7KCIoOzs7Ozs7 Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozs7Ozv/wAARCAJZAAgDASIA AhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQA AAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3 ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWm p6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEA AwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSEx BhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElK U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3 uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDYopaK 9U+CCilopDCiiigYuKKWikMWilooKCinUUhi4opaKCrC0UuKKRVhcUU7FFBQtFLRSKFxRS0Uhi0U tFAwxRS0Uhi0UtFAxaKKKBhRS0UDCiiigBaKKKACiiigYUUUUCCikooAKKKKAEooooEFFJRQAlFJ RQITNFFFMQlFJRQITNFJRTJEopM0UCuNzRSZopkiUUlFMkTNFJRQSNooopiuJRSUUEiZopKKZIUU UUCEooooASiiimSf/9m= ------=_NextPart_01C7EB01.76A7EDC0 Content-Location: file:///C:/9282BE47/drugpatchblog_files/image005.jpg Content-Transfer-Encoding: base64 Content-Type: image/jpeg /9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAoHBwgHBgoICAgLCgoLDhgQDg0NDh0VFhEYIx8lJCIf IiEmKzcvJik0KSEiMEExNDk7Pj4+JS5ESUM8SDc9Pjv/wAALCACIAPgBAREA/8QAHwAAAQUBAQEB AQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1Fh ByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZ WmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXG x8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/9oACAEBAAA/AOM+Hvw9/wCE8/tD/iaf YPsXlf8ALv5u/fu/2lxjZ+tdn/wz3/1NP/kh/wDbKP8Ahnv/AKmn/wAkP/tlH/DPf/U0/wDkh/8A bKP+Ge/+pp/8kP8A7ZR/wz3/ANTT/wCSH/2yj/hnv/qaf/JD/wC2Uf8ADPf/AFNP/kh/9so/4Z7/ AOpp/wDJD/7ZR/wz3/1NP/kh/wDbKP8Ahnv/AKmn/wAkP/tlH/DPf/U0/wDkh/8AbKP+Ge/+pp/8 kP8A7ZR/wz3/ANTT/wCSH/2yj/hnv/qaf/JD/wC2Uf8ADPf/AFNP/kh/9so/4Z7/AOpp/wDJD/7Z R/wz3/1NP/kh/wDbKP8Ahnv/AKmn/wAkP/tlH/DPf/U0/wDkh/8AbKP+Ge/+pp/8kP8A7ZR/wz3/ ANTT/wCSH/2yj/hnv/qaf/JD/wC2Uf8ADPf/AFNP/kh/9so/4Z7/AOpp/wDJD/7ZR/wz3/1NP/kh /wDbKP8Ahnv/AKmn/wAkP/tlH/DPf/U0/wDkh/8AbKP+Ge/+pp/8kP8A7ZR/wz3/ANTT/wCSH/2y uM+IXw9/4QP+z/8Aiafb/tvm/wDLv5WzZt/2mznf+ldn+z3/AMzB/wBu3/tWvZqKKKKKKKKKKKKK KKKKKKKKKKKKKKK8Z/aE/wCZf/7ef/aVH7Pf/Mwf9u3/ALVr1S58Q6NZT3EF1qlrBLbIHmSSUKUU 9Cc+tc7d/FzwTaxuw1fz2Q42QwuSeccEgA/nVH/hd3g7/npe/wDgP/8AXqxd/GPwValNmoTXO7Of Jt3+X67gK4XxF8dtSmvQvh60jt7ZDy9yu95fwBwo/M+4rMPxy8XEfc04f9sG/wDiqybr4reNruIR vrciAHOYokjP5qAaLb4r+NrWHyk1t3Gc5lijdvzKk1q2Hxv8W2uwXP2O9UHLGSHazD0ypA/Suu0T 49adPtj1vTJbR+8tufMTv2OCO3rXo+meJdE1iGKXT9VtbgTfcVZQGPttPIPtitOiiiiiiiiiiiii iiiivGf2hP8AmX/+3n/2lWP8I9Ivtc0LxNp+natJpc0htf8ASI1yduZcjqCM+oIrQ1H4Ea3PL50f iOC8kckyPco6sT9ctnvWD/wpLxl/zys//Agf4Vk638M/FmgxGa600yQjA8y3cSZJ7YHzfpWHfaJq 2mM4v9Nu7by8b/NhZQuemSR7iqNFFFFFAJU5BII7it7w9428QeGbhJNO1GURqctbyMXicdwVP8xg 19B+BPHth4104sgW3v4R/pFqWyR/tL6qf06fXq6KKKKKZLNFbxNLNIkca/ed2AA/E1zmsfETwrok TvcavbzPGwVobdxJJk/7INZkHxg8H3F3FCt86I8LSvNLGUWPH8JzyWPYAGoF+Nfg0uF8+7AJxuNu cD3rT034n+E9V1k6VbakBNu2o8i7Y5DnGFY9Se3rXW0UUUV4z+0J/wAy/wD9vP8A7So/Z7/5mD/t 2/8AatezUUUjKrqVZQwPYjNY2oeDvDWqNvvdDsZXLFi/kgMSe5I5NeKfFH4fyaHqRu9D0SSLSFhD STRu0gDZOS2SSoHA9K84ooopdw8vbsGc53c5+npSVe0TWbzQNXt9TsJDHPbuGHJww7qcdQRwRX1X 4e1y18R6Fa6rZsDHcICV7o38Sn3ByK06KxPEnizSfDFnLLfXcAnWIyx2rTKkkoHZQTzXl93+0BcF l+xeH4kXHzedcFiT7YArBufjf4wnjKRGxtiTkPHb5Ye3zEj9K5bWPFviPxE8rajql1OjqN8SsVjw Dn7gwvX2qs+hagBNJ9inhjhtluWMylf3Z2gMOOQSwx9azqKK2NP8X+I9KULZa3ewqF2hBMSoHsDw K6XQPjF4n0eSU3k39qxuOEuTjYfUEDP4V1UHx/Vry1+0aG0dsFb7T5cu9yccFM4GM569jXVaP8Yv CGqskct3Lp8jdrtNqjnH3hkD15Nd0CCMjoa8a/aE/wCZf/7ef/aVH7Pf/Mwf9u3/ALVr2aiiiiq9 9Y2upWUtlewrPbzLtkjbow9K+f8A4p+AbnQtUm1XT9Nht9GcoieQ5ba23ksp5XkH2/OvO6KKKVUZ lZlUkIMsfQZx/WkUgMCQGAPQ969X+E3iefwuiRavH9n0PV5mFrcM3ypMuAR1yFI4JPcD3r3KWaOG B55HVYkUuzk8AAZJrxLxR8dL2aSa18OWqW8QO1buYbnYc8hegzx1z/h5Ve311qV5Jd3txJcTytue SRskmoKdGUEimQFkBG4KcEjvg1rvq1ppOrXc3h1ZhaXFu0G2/VXcK64cHHB74NUI9Suwhikurh4H UI8QmYBkHIU+w9KZZ2N3qFwtvZW0tzM3SOJCzHt0FdnpHwc8X6phprWLToyMhruTB6Z+6uT+Yrut J+AmkwBW1bVbm6bHKQKIlzn1OT0rrdN+GXg/SrgT2+iwu4Qp/pBMowTnOGJGfetiTw1oMxBl0TTp CBgFrVDgenSl03w7o2kLKun6Zb2yzPvcIgwTVifTbC6haG4sbeaJvvJJErKfwIqz0GBXjX7Qn/Mv /wDbz/7So/Z7/wCZg/7dv/atezUUUUUUjKrqVZQynqCMg14p8cPD0FqNMutL0cQp+9+0S21uFTPy kbyo68Hr714/RRRRV6PV7mPRptJZUltpZFlXzASYXHUpzxkcH1AHpV251qebRrPT7LU9XLMhjubS SctCxzxsAPQ/3SOverUXw88VT6ENZi0iZ7YnhVwZCP72zriuckjeJzHIjI69VYYIqS3s7m7ljitr eWaSZ9kaxoWLt6DHU8ivT/DXwL1DULQXOu3v9nFx8tvGgeQc/wAXOB9Oa6G2+AWjJMGudYvZo8co iKh/Pn+VdFpnwl8G6agB0v7W/GXupC5OPbgfpXV2en2WnxCKys4LaMdFhjCD16AVZoooooorxn9o T/mX/wDt5/8AaVH7Pf8AzMH/AG7f+1a9mooooooqhrlhPqmiXlhbXbWc1xE0aTqMlCe+K8A8U/CD XvD4gaxEmrpLu8xreEjysDPIyeozz7e9cDVqaz+xS2xneKWOZEl/cyq+FPY4Pyt6g8itbxRd+Gl1 uGTwnZyxWkKgk3R3iR+v3WzwOnPWsFH2Nu2q3BGGGR0ptXtG1C40zVbe6tppIZFkHzxKpdef4c8Z r3bw/wDFXQJJZLO81a7im+WKJNSt1i2Mq4Jd0yPmPJJxjngV1bXq/wBhPfTWlheaiLRrkQW0gdZg BkFWIBKnjnHevLoPjs8E0Xm+HLTyh8x8ibDLkdvl4Neh2/xO8GXBjQa9bI8mBhwygE+pIwPrXUo6 yIrowZWGVZTkEetOoooooooorxn9oT/mX/8At5/9pUfs9/8AMwf9u3/tWvZqKKKKKRmCqWYgADJJ 7V5h4m+Nthour3Wn6fYDURAAonWbahf+IdOQOOR71w2sfGvxRqcM1vbpa2MMoZf3SEvtIxjcT1Hq AK88pUcxurrjKnIyAR+RpKKKVVZ2CqCzE4AA5JrrNM+GPjLWYjcRaTLEp5DXTCIt+Dc11P8Awp3x 1dxWwutbtgIohGiSXUrGFOPlHy4wMdAccVHdfAPX0lAtNV0+ZMctJvjOfTAB/nXQab8GGfwvc2Gr f2amoFl+zXlskhZBkE7skBsjIxj8fT0vQtJi0HQ7PSoHaSO0iEYd+rY6n8+3ar9FFFFFFFFeM/tC f8y//wBvP/tKj9nv/mYP+3b/ANq17NRRRRRUV1bQ3tpNaXCCSGeNo5EP8SkYI/I14f4v+C19bTXl 7oCRyWiBPs9ojM8zk4DZJ445PXp2rjrX4b+MLtI5E0G5RJD96bEe3nGTuIIH1rO17wzq3hqaOLVL dYvNz5bpIrq+MZwVJ6ZFZVFa2k+FNf10FtM0i6uUAzvWPC9v4jxnkcV2fhX4Na5qMskutW4sYE4V JJcO7cegPGM17BoHgPw3oCQyWuj2q3SYbzmBkZW9VZuR19q6OiiiiiiiiiiiiivGf2hP+Zf/AO3n /wBpUfs9/wDMwf8Abt/7Vr2aiiiiiiioL2yttRsZrK7iEtvOhSRD0ZT1Feej4GeFhdeYbnUWhDFh AZl2jPbO3Pp3zxW1F8KvBMcSp/Ycb7QBuaVyT7n5qu2HgDwlpr77bQLMOGDBpE8wqR0ILZx+FdAq qiBEUKqjAAGABTqKKKKKKKKKKKKKKK8Z/aE/5l//ALef/aVH7Pf/ADMH/bt/7Vr2aivMNe8barb/ ABj03QLO+VLDMcdxCFB3MwJOSec4I6e1TfGLXda8N2Gn32j6nPaNLK0UiKqsrDGQeQeat2t3qer/ AA70S+tNduI767lgElwCnzFnCyLgrjj5sYHUelcvd+JfEMPxgXwumuXf9nG4jj2nZvwYwx+bb6mu qul17S/iRpWn/wBt3c+j6lBN+7kVN0cixk43BfoR+PpXI+CvE/iPxB4x1TSL3XrwW9tbzvEYxGGV lcBTnbzwa6X4XeO7zxpp97YamwS+tlGJ4V2lkbjd3AYH8OnHWsLwT4p8Qy/E+48Oa7rNxcxwNNHG oVFDOh43EKCRtDfjiu90mDUpfGGrzyazNNp1uyRw2nyELIyBmyQucDIwM9+ap/FLU9Q0XwZPqemX strcwSIFZNpBDMAcgg54pvwr1TUdb8HR6nql7LdXM0rqWfaAApIGAAMV1WoXaafptzeSMqJbwtIz N0AUE8+3FcD8HvFWseKLLVX1e7+0NDMnlfKFKhgcjjtxWHD4p8RQ/GZfDkmtXMmmi72+W6oCV2bg uducZ4+lN8V+MNc0f4sQ6Omtzw6U9xAZVIQ7UfBYA7cgcmvRnivn8cpt1WdbJLLzXswF2s+7aDnG cYzxnrj3qv8AEW9vNL8E3+o6fdy2tzaqro8eO7AYIIORg1zHw9ufEHjHwTeX0/iK8i1Fbh4oZVEe xcKpGV24PJOawta8XeKbD4YaVq51a4i1Nr+W1nbYgyFMnBUr1G0CtTWfEOuWfwd0/wAQw6vcrqMr IXlIQhtxwRjbjHHH1NZcnjjxHpXw80XxUNUkuru5vJIZ4bhFMUigvjgAEH5R0Pc13Wv6zd6r8OF1 3QruSyuZoo5YW4wCWAKtkHI5NYXw48YavrXgbWbvU7ppru0dlinKgHJQbRgDHB/nWZ8JfFXiLxH4 nu7bWdWmuI7W3LiPaigtuC84HPU17DRRXjP7Qn/Mv/8Abz/7So/Z7/5mD/t2/wDatezUV86ePiLL 4jWniBpDcR3VwLgKo2nbFKYwB9VjHPvXpXxstpLj4eSSpt229zFI+T2JK8fiwqh8L7t77wj4btHg Qi3vLhgx7Kqvzz3zL+lcpq00Vv8AtEedPIkUaXcRZ3bAUeUvU16R4Ykg8WtF4ihZglrqty0GWJ3R mMx9Pfg+3NeZfDKWKD4ka5JNIkaC1uss7AD/AFi+tdH8CvDt/YR6jq95by28VyqRwCRNvmAZJYZ5 x0+uaxfH4/4Rf40WGs5CxTvDcOfvfLnY/B9lNeweGh5mk/bTnN9NJc8tu+VmO3kf7O2uc+Mv/JN7 3/rrD/6GKZ8F/wDknNr/ANd5f/Qq6Txan2jw5c2Il8pr8raBtu4/vGCHA+hJ/CvJvgVKLPxXrGms CzmDO8dPkfB/Pd+lRfEX/iV/GzTb+45hZ7WcBOW2q208euVNVPi9Gtv4mtNZRSbiWaUMSflYRMqp gfgQa9o0dmudZ1G8eJUPl28Wc8khC5+g/eD8jWZ8U/8Akm2s/wDXJP8A0YteffDbxFa6Z4MsdLEq m81HxBHGkavhlTMRZiPTjHvmrvxi0saR4ItoFbcsusyTj28wSOR+ZNQ+I/8Ak3jSv+2P/oRrAvbe bUfgv4bsLKNrm7fUZSsEQ3ORmTnaOccj869Yg0N9P+Hem6JdMQ6i2hlIxlS0ihgOo4yfyry/4RTx +ZrekFnb7U9sAo6FBLtf8drZ+gJ7VZ+BZz4y1YnvaN/6MWvdaKK8Z/aE/wCZf/7ef/aVH7Pf/Mwf 9u3/ALVr2aoL24W0sLi5clVhiaQkDOAAT0rwn4vWkdtpnhaZATOtqyTOWyQw2tg9gcs/6+lej+LC mu/B+5uG/wBLMunpOGUfecANu49xmuP+AoM/23KswtN2GY8IZNuAPr5bZrN1AZ/aNUH/AJ/Iv/RS 16ZpAj8MX8WjRW5jj1PVLl4QVAVU8syHbjoMjA9s15R8ObK1v/iJrlveW0VxCba5JSVAwz5i8811 nwQ8Vajq1tfaRqM8t0bQLJDLK+4qp42ZPYY4+prK/aC/4/dD/wCuc380r2DSf+QPZf8AXvH/AOgi uR+Mv/JN73/rrD/6GKZ8F/8AknNr/wBd5f8A0KtOHWotei0K5YtFHPdzTY+6NkW9VLE9OdnHqa8w 8CSx6T8cL+zicQQSzXMKp1DLksoBP0Bqz8eoTba9o2oQxlJTCy+bjjKsCo9OMk/jTfijDc3Pw58M 6pKUPmyPLJg87ph5g/rmvRvhqWm8G2t4/mFroBt0jZZgqqg7nslJ8U/+Sbaz/wBck/8ARi1xPwu0 ePVPh/BL5Reey16O4iKqCwwYt3Pptzn6VpfHz/kUdP8A+v8AH/ot6yfEf/JvGlf9sf8A0I1gTzya N8IvDus6Y32PUhfSx/aoRtkKZkO0kdRwOD6V7Baau2veDNJ1V4/Le6ltHZewPnJnHtmvLfA9lcW/ xvv7RnECxXFxK8SgEMATtHt94Hj0p3wJ/wCRx1b/AK9D/wCjFr3aiivGf2hP+Zf/AO3n/wBpUfs9 /wDMwf8Abt/7Vr2asDxtJdr4XuYbKxur2W4KwmO1OH2MfnOe3y5/EiuM+K/hd9Y8Pad/YGisZxNv aOC02Nt24+bAGMccGuk8KWl3d/DSLR760n0+6Wya0dJUOQdpUMPXIwfxxWN8GPDWoeH9D1BtU0+S zubm5GBJwzIq8cduS1c5faFrTfGr/hIU0a/bTVuo3MwgPRYwpOOvUGuqubvVdW+JmkXq6HqMGlaZ Dcbp5oSu92QjIXOccADjPJrk/h94d1vSfHuo3+oaRfW9rdxTRRytASMu6kZx0GKl+GvhbxP4V17U rWfTbiJpxGiXYCmIKrgsc57r0AyefarXxp0DWfEOoaWuk6XdXYto5BI0cZ2jcVxz36GvUNHLHRrP dHJGywqrJIpVgQMHIP0rmPitY3uq+CJ9P0+znurmaSMokKFuFYE59OKwPC02ueGPhg+mR6BqUmrk yiKIW52qWJwxbpgdfWp/BFldq2kaZrWgXois9PePzLiDdEJnl3NkEHnaFw3uRXP3XhvWNN+Mi65Z aFczaYl0pLQ25VVUrtYgY5xyeOtdH8ZfDep+I9F0x9KtZrqaG4IMKLztZfvHPTBUD8asfEvwzcan 8OrbT9OsJJbmzeEwwQD7uBtPHoATXT+D9OOk+D9JsXieKSK1TzI5D8yuRlgfxJqh8SLa6v8AwLqN jZWs11c3KqkccKFiTuB59BgGsb4O6dqGieGZ9M1TT7q0uDdPMBLEQpUqgHPTOQePao/jNpOpa5oF jY6Vp9xeTpdCVhFGSAoRhyenUjisrW9H1a6+C2m6HDpN62oRsivB5Jyu05JPtyPrWXdeD9e1H4QW GjxaZcpqGnXbzyW8kZUurF/uk8McMDgV0mkT65pPgzSrWbw/qkv2cW6G2jiUuGjl3u/XgYAAz1Pb vVjw/oF1p3xO8Ra/JZz/AGGe2R4nePLs7hWYKAM8YII69K534QeHtb0HxXezappF5axXNuUjkeI7 d24NgntwDXstFFeM/tCf8y//ANvP/tKj9nv/AJmD/t2/9q17NRRRRRRRRRRRRRRRRRRRRRRRRRRR RXjP7Qn/ADL/AP28/wDtKuM+HvxC/wCED/tD/iV/b/tvlf8ALx5WzZu/2Wznf+ldn/w0J/1K3/k/ /wDa6P8AhoT/AKlb/wAn/wD7XR/w0J/1K3/k/wD/AGuj/hoT/qVv/J//AO10f8NCf9St/wCT/wD9 ro/4aE/6lb/yf/8AtdH/AA0J/wBSt/5P/wD2uj/hoT/qVv8Ayf8A/tdH/DQn/Urf+T//ANro/wCG hP8AqVv/ACf/APtdH/DQn/Urf+T/AP8Aa6P+GhP+pW/8n/8A7XR/w0J/1K3/AJP/AP2uj/hoT/qV v/J//wC10f8ADQn/AFK3/k//APa6P+GhP+pW/wDJ/wD+10f8NCf9St/5P/8A2uj/AIaE/wCpW/8A J/8A+10f8NCf9St/5P8A/wBro/4aE/6lb/yf/wDtdH/DQn/Urf8Ak/8A/a6P+GhP+pW/8n//ALXR /wANCf8AUrf+T/8A9ro/4aE/6lb/AMn/AP7XR/w0J/1K3/k//wDa6P8AhoT/AKlb/wAn/wD7XR/w 0J/1K3/k/wD/AGuj/hoT/qVv/J//AO10f8NCf9St/wCT/wD9rrjPiF8Qv+E8/s//AIlf2D7F5v8A y8ebv37f9lcY2frX/9n= ------=_NextPart_01C7EB01.76A7EDC0 Content-Location: file:///C:/9282BE47/drugpatchblog_files/image002.png Content-Transfer-Encoding: base64 Content-Type: image/png iVBORw0KGgoAAAANSUhEUgAAAWkAAAC/AQMAAAAGpb+LAAAAAXNSR0IArs4c6QAAAARnQU1BAACx jwv8YQUAAAAgY0hSTQAAeiYAAICEAAD6AAAAgOgAAHUwAADqYAAAOpgAABdwnLpRPAAAAAZQTFRF AAAA////pdmf3QAAAAlwSFlzAAA3XQAAN10BGYBGXQAABMVJREFUaN7t2c1qHDccAHBNJqz6kVaG HrqHNDL0BXzc0s0qt76GHyG3+tB6tLjgYx/BfYRcCy0Z44KPeYSMCcS3MsbGOybqqPqYD2lG0mih EAo7YNjV/qz96/+XNBob8G0uCnZ8x3f8o3OWxvOaMwAAieUlUFcsLzSHkZyCmO5bXjca4GleANJq kE7yApjXFD+1dDiXgv9lczDBBzoYPQXlkIMsxIsRxyGejzjcjqchPg4GhHg7F6PGKqs6Cseu1NmA j37BTE09ewYWxOa1zZHJwRzsYZuzhTeT1Gpo57uVHyOTpd3QrSaTJ0Pe5arjlTPx9eD7+n3GDKdL fDXooedtR58Y3MgY8XCjTlbTB5uzcZ3kS9q2VVN8UGs/R6PcNtlxx476gibWiIwNm/YfQCeHFi8H s0C/v7CKHeCqbnu3ETzpYpn/oFs+E+O5CXL1at41IDuR1li7xD7V778dTTGzLPvdl+1ZE9LD5RxT 78QqewGMte4JhjRVW9qd+3llhI75RDB4lKcxN9YfMhcXcvN+Tqan5lfxMN8H6YnBoYf3EzxdG+Mm Pt7Fm9DMnm5O3ndvRE4i+KEz8giexfDOYx7gfTpejocZ6n0xrGeYO7IS5EkOHLdAL4elNRWd3KgO ZK67vc2NKZxxmvw6wY1tlTsvV++Pxc+jGF42nDpS7uMr9TtPYrk+U85jY9e9ZyzL0QRX3eutiLCM TpVJ8Xm7uUTxtrKY/zLJWX82g3JKZGHez5p9sMnHR0ov3wO3+bhYXg7UaRdOcKr3f/e24eTGdTzB rTOTGOlE7IOlDYO8LgcckRBnNl6NT/IBzh2Xxa2BZpPcDN195nffPYDvAYTa97WJWPycb8VRBM+n YvHl3fcs5Mk72Y6DGM4Ot+q9rxOP5EftnhTDWcZDeXH8ScQ/X1x8HYp8zF27RYDTYOeOXYzzLXiJ tuIT147/j/hVLQ+OibirUyR/eI0LCJZI7CQHsjXHzXFC84IDtkDrYpHl5IQX4rkGlSg/xjwpl1C0 ljgnBs85rY/QebHEBbmUnKEK5RnhSSX4Ejv5leJvLM40R26OLJ41HDl4hW7kB/itxWvF7zwcOjm8 Q7+ZnHJ6bPFKchLmD4qfWZw7eZb/pHmFXisOGcxXAf5zhX4fcs6Tjebwv+JkmgPF/xQfMJhJXooX rxT/Q/NDk7/I8ucWv5P8WcfvXfy5qN+QX0uOBvyQ5N+JqCWfKX6fCv5UcubkxffVl5LX4rFA8Tp9 9Y3gl5qnbo6dHNu8VvyJ4KTh71t+KjkZ8EJyQIoFr4Hifwv+UnDx+CQWH79/VIy46F3c8pKOH7W9 pw7+lYz9wOJfNLEf8M2If60SSUz+aZtIYnNW4lJz3PA3CU+OPm853gCT/zPibyO4mDNI803HN6pM ERyYPHFzaPCq43DMoV4eml9LLv9r4uQPgiOLn0kOe742+YcSSf7Q89eg4dzF5bZic7HzeHkFhlw0 06nebzp+Oez9xOS3I04oXwc51jxz8h8tvhny00zwGoX5lZ9fmPxa7HEWn2U0O/fyd0zx82I100Od kdzgq9k7i19onhQroPjysc3B+aXJ8zJhpBB3bXjC5N9CxLMEwBeCM0BK2UovqXnXjr52fMd3/GPx fwFqhTXHCxC5+QAAAABJRU5ErkJggk== ------=_NextPart_01C7EB01.76A7EDC0 Content-Location: file:///C:/9282BE47/drugpatchblog_files/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/xml; charset="utf-8" ------=_NextPart_01C7EB01.76A7EDC0--